291 related articles for article (PubMed ID: 17115578)
1. A pox on your practice. iPLEDGE program scars dermatologists.
Ortolon K
Tex Med; 2006 May; 102(5):29-31. PubMed ID: 17115578
[No Abstract] [Full Text] [Related]
2. The cost of clear skin: balancing the social and safety costs of iPLEDGE with the efficacy of Accutane (isotretinoin).
Doshi A
Seton Hall Law Rev; 2007; 37(2):625-60. PubMed ID: 17294569
[No Abstract] [Full Text] [Related]
3. [Dermatology under threat].
Cattan E
Ann Dermatol Venereol; 2006; 133(8-9 Pt 1):704; author reply 705. PubMed ID: 17053744
[No Abstract] [Full Text] [Related]
4. We Pledge to Change iPLEDGE.
Pierson JC; Ferris LK; Schwarz EB
JAMA Dermatol; 2015 Jul; 151(7):701-2. PubMed ID: 25853235
[No Abstract] [Full Text] [Related]
5. Isotretinoin and iPledge: a view of results.
Maloney ME; Stone SP
J Am Acad Dermatol; 2011 Aug; 65(2):418-419. PubMed ID: 21763564
[No Abstract] [Full Text] [Related]
6. Accutane risk management program strengthened.
FDA Consum; 2002; 36(1):8. PubMed ID: 11881607
[No Abstract] [Full Text] [Related]
7. Concomitant use of isotretinoin and contraceptives before and after iPledge in the United States.
Pinheiro SP; Kang EM; Kim CY; Governale LA; Zhou EH; Hammad TA
Pharmacoepidemiol Drug Saf; 2013 Dec; 22(12):1251-7. PubMed ID: 23913625
[TBL] [Abstract][Full Text] [Related]
8. Prescribing Isotretinoin for Transgender Patients: A Call to Action and Recommendations.
Sanchez DP; Brownstone N; Thibodeaux Q; Reddy V; Myers B; Chan S; Bhutani T
J Drugs Dermatol; 2021 Jan; 20(1):106-108. PubMed ID: 33400408
[TBL] [Abstract][Full Text] [Related]
9. Accutane registry compulsory in US, but not Canada.
Andresen M
CMAJ; 2006 Jun; 174(12):1701. PubMed ID: 16754892
[No Abstract] [Full Text] [Related]
10. Does the teratogenicity of isotretinoin outweigh its benefits?
Jordan AY; Parks L; Chen SC; Higgins K; Fleischer AB; Feldman SR
J Dermatolog Treat; 2005; 16(4):190-2. PubMed ID: 16249139
[No Abstract] [Full Text] [Related]
11. Administrative Burden of iPLEDGE Deters Isotretinoin Prescriptions: Results From a Survey of Dermatologists.
Lee G; Wolf JR; Somers KE
Cutis; 2022 Jul; 110(1):44-47. PubMed ID: 36179224
[TBL] [Abstract][Full Text] [Related]
12. Coping with the isotretinoin registry.
Baldwin HE
Dermatol Ther; 2006; 19(4):241-50. PubMed ID: 17005000
[TBL] [Abstract][Full Text] [Related]
13. The power of Accutane. The benefits and risks of a breakthrough acne drug.
Meadows M
FDA Consum; 2001; 35(2):18-23. PubMed ID: 11444244
[No Abstract] [Full Text] [Related]
14. The need for restricted prescription of retinoic acid derivative isotretinoin to prevent retinoid teratogenicity.
De Santis M; Straface G; Cavaliere A; Nobili E; Caruso A
Prev Med; 2007; 45(2-3):243-4. PubMed ID: 17640721
[No Abstract] [Full Text] [Related]
15. Safe use of acne drug.
FDA Consum; 2005; 39(6):4. PubMed ID: 16669109
[No Abstract] [Full Text] [Related]
16. Isotretinoin prescribing: finding a balance between benefit and risk.
Stern RS
Pharmacoepidemiol Drug Saf; 2005 Sep; 14(9):611-3. PubMed ID: 16134100
[No Abstract] [Full Text] [Related]
17. Healthcare professional surveys to investigate the implementation of the isotretinoin Pregnancy Prevention Programme: a descriptive study.
Crijns I; Mantel-Teeuwisse A; Bloemberg R; Pinas E; Straus S; de Jong-van den Berg L
Expert Opin Drug Saf; 2013 Jan; 12(1):29-38. PubMed ID: 23163396
[TBL] [Abstract][Full Text] [Related]
18. [Guidelines for the good use of isotretinoin in private practice: a prospective observational study of 1263 acne patients].
Jeanmougin M; Beaulieu P; Doutre MS; Jaramillo C
Ann Dermatol Venereol; 2009 Jan; 136(1):54-6. PubMed ID: 19171232
[No Abstract] [Full Text] [Related]
19. Acne drug controversy ignites turf battle over prescribing.
Thomas P
Med World News; 1988 Jun; 29(11):46-7. PubMed ID: 10313737
[No Abstract] [Full Text] [Related]
20. Family physicians and accutane.
Van Durme DJ
Am Fam Physician; 2000 Oct; 62(8):1772, 1774, 1777. PubMed ID: 11057835
[No Abstract] [Full Text] [Related]
[Next] [New Search]
